158: Bexicaserin, the PACIFIC Trial, and Treating Developmental Epileptic Encephalopathies

About this episode

This episode discusses the PACIFIC trial findings on bexicaserin for treating developmental epileptic encephalopathies with insights from Johannes Streffer.

Welcome to the NeurologyLive ® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, "Bexicaserin, the PACIFIC Trial, and Treating Developmental Epileptic Encephalopathies," Johannes Streffer, MD, PhD, discusses phase 1/2 findings from the PACIFIC trial evaluating bexicaserin in developmental epileptic encephalopathies, presented at the American Epilepsy Society 2025 Annual Meeting. Streffer, senior vice president of clinical development at Lundbeck, outlines the scientific and clinical rationale for studying DEEs as a unified population, emphasizing the unmet need and complexity of trial design in this highly vulnerable group. He reviews key efficacy outcomes, including sustained reductions in countable motor seizures and strong patient retention through long-term open-label extension and expanded access follow-up. The discussion also explores safety and tolerability considerations in patients receiving multiple concomitant antiseizure medications, the highly selective mechanism of action of bexicaserin, and how Lundbeck’s broader strategy in rare neurological disorders aims to de-risk development…

People in this episode

Host: Johannes Streffer

Guest: Johannes Streffer Md Phd

Topics covered

• bexicaserin
• PACIFIC trial
• developmental epileptic encephalopathies
• neurology
• clinical trials

Keywords

• epilepsy
• clinical development
• antiseizure medications
• safety
• tolerability

Mentioned in this episode

Products: bexicaserin

Books & works: Neurology News Minute

More episodes of NeurologyLive® Mind Moments®

• 168: Analyzing Phase 2 Data for PACAP Targeting Therapy Bocunebart in Migraine · June 12, 2026 · 18 min
• 167: New AASM Guidance on Combination Treatment for Chronic Insomnia · May 29, 2026 · 20 min
• 166: Understanding RNFL Asymmetry as a Biomarker in Pediatric MS · May 15, 2026 · 15 min
• 165: Addressing Cognitive Decline in Parkinson Disease · May 1, 2026 · 20 min
• 164: Tremor vs Dyskinesia: Practical Bedside Clues for Clinicians · April 17, 2026 · 25 min
• 163: The Clinical Reality of Seronegative Myasthenia Gravis · April 3, 2026 · 17 min